Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Trial Profile

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2018

At a glance

  • Drugs STRO 001 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sutro Biopharma
  • Most Recent Events

    • 13 Aug 2018 According to a Sutro Biopharma media release, this clinical trial is currently open and enrolling patients at City of Hope Comprehensive Cancer Center, Medical College of Wisconsin,Texas Oncology, Rocky Mountain Cancer Centers and Virginia Cancer Specialists. Sutro plans to add more sites later this year.
    • 13 Aug 2018 According to a Sutro Biopharma media release, the company and the Leukemia and Lymphoma Society (LLS) are partnering to develop STRO-001 to treat relapsed and/or refractory multiple myeloma and non-Hodgkins lymphoma. LLS has agreed to contribute clinical development funding for STRO-001 through its Therapy Acceleration Program and Sutro intends to use this funding for this trial
    • 05 Jun 2018 This study is currently open for enrollment in the US as per trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top